- Home
- DYN
as 06-06-2025 4:00pm EST
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.3B | IPO Year: | 2020 |
| Target Price: | $45.92 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.36 - $47.45 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | DYN | Chief Commercial Officer | Mar 13 '25 | Sell | $12.12 | 143 | $1,733.16 | 96,057 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 11 '25 | Sell | $11.38 | 1,343 | $15,283.34 | 122,330 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Mar 11 '25 | Sell | $11.38 | 2,153 | $24,501.14 | 195,840 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
MT Newswires
5 days ago
Oppenheimer Adjusts Dyne Therapeutics Price Target to $34 From $60, Maintains Outperform Rating
Yahoo Finance
7 days ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
7 days ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
7 days ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Reuters
7 days ago
Ford recalls more than 29,000 vehicles in the US, NHTSA says
USA TODAY
7 days ago
Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
Simply Wall St.
7 days ago
Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.